More Problems For Biogen's Tysabri
This article was originally published in The Pink Sheet Daily
Executive Summary
The most recent disappointment for the big biotech, which has been plagued by a host of issues, comes from a late-stage failure in its multiple sclerosis program, prompting pipeline discontinuations.